17-43094135-G-C

Variant names:

• chr17-43094135-G-C
• rs80356964
• NM_007294.4:c.1396C>G

Variant summary

Our verdict is Uncertain significance. The variant received 0 ACMG points: 0P and 0B.

The NM_007294.4(BRCA1):​c.1396C>G​(p.Arg466Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000205 in 1,461,768 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R466Q) has been classified as Likely benign.

• Frequency:
  • Genomes: not found (cov: 32)
  • Exomes 𝑓: 0.0000021 (0 hom.)
• Consequence: BRCA1 NM_007294.4 missense
• Clinical Significance: Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:13 B:1
• Conservation: PhyloP100: 0.776
• Publications: 13 publications found

Genes affected

BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]

BRCA1 Gene-Disease associations (from GenCC):

• breast-ovarian cancer, familial, susceptibility to, 1

  Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
• Fanconi anemia, complementation group S

  Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
• pancreatic cancer, susceptibility to, 4

  Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
• hereditary breast ovarian cancer syndrome

  Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
• Fanconi anemia

  Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

ACMG classification

Our verdict: Uncertain_significance. The variant received 0 ACMG points.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
BRCA1	NM_007294.4	c.1396C>G	p.Arg466Gly	missense_variant	Exon 10 of 23	ENST00000357654.9	NP_009225.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
BRCA1	ENST00000357654.9	c.1396C>G	p.Arg466Gly	missense_variant	Exon 10 of 23	1	NM_007294.4	ENSP00000350283.3

Frequencies

GnomAD3 genomes Cov.: 32

GnomAD4 exome AF: 0.00000205 AC: 3 AN: 1461768 Hom.: 0 Cov.: 34 AF XY: 0.00 AC XY: 0 AN XY: 727174

African (AFR) AF: 0.00 AC: 0 AN: 33474

American (AMR) AF: 0.00 AC: 0 AN: 44722

Ashkenazi Jewish (ASJ) AF: 0.00 AC: 0 AN: 26130

East Asian (EAS) AF: 0.00 AC: 0 AN: 39686

South Asian (SAS) AF: 0.00 AC: 0 AN: 86244

European-Finnish (FIN) AF: 0.00 AC: 0 AN: 53380

Middle Eastern (MID) AF: 0.000520 AC: 3 AN: 5768

European-Non Finnish (NFE) AF: 0.00 AC: 0 AN: 1111976

Other (OTH) AF: 0.00 AC: 0 AN: 60388

GnomAD4 genome Cov.: 32

Alfa AF: 0.00 Hom.: 0

ClinVar

Significance: Conflicting classifications of pathogenicity

Submissions summary: Uncertain:13 Benign:1

Revision: criteria provided, conflicting classifications

Submissions by phenotype

Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:5

Oct 17, 2024

Diagnostics Centre, Carl Von Ossietzky University Oldenburg

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

The variant BRCA1:c.1396C>G p.(Arg466Gly), located in the coding exon 10 of BRCA1 gene, results from a cytosine to guanine substitution at nucleotide position c.1396. The arginine residue at protein position 466 is replaced by a glycine. This amino acid position is not highly conserved in the available vertebrate species. The impact of the variant in the protein structure/function is assessed as unclear by in silico tools (Revel = 0.593). The variant has been reported in multiple patients affected with breast cancer (PMID:22425665; 30199306). This variant has been classified in eight entries as variant of unclear significance and once as a probably benign variant (ClinVar ID: 54240). This variant is classified as very rare in the overall population (MAF 1,8 * e-6 in gnomAD, v4.1.0). In summary, the variant is classified as variant of uncertain significance.

May 05, 2023

KCCC/NGS Laboratory, Kuwait Cancer Control Center

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

a variant of uncertain significance in the BRCA1 gene (p.Arg466Gly). The p.R466G variant (also known as c.1396C>G), located in coding exon 10 of the BRCA1 gene, results from a C to G substitution at nucleotide position 1396. The arginine at codon 466 is replaced by glycine, an amino acid with dissimilar properties. This alteration was identified in Moroccan and Saudi Arabian high-risk breast cancer cohorts (Tazzite A et al. Gynecol. Oncol. 2012 Jun;125:687-92; Abulkhair O et al. J Glob Oncol, 2018 08;4:1-9). This amino acid position is poorly conserved in available vertebrate species. In-silico analysis showed conflicting results. ClinVar has an entry for this variant with 6 submissions, two stars, and no conflict. This variant is not found in gnomAD genomes. Currently, the pathogenicity of this variant is not clear. Therefore, it is classified as variant of uncertain significance. Pathogenic/likely pathogenic mutations cause hereditary breast/ovarian cancer syndrome (HBOS).

Department of Pathology and Laboratory Medicine, Sinai Health System

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

The BRCA1 p.Arg466Gly variant was identified in 1 of 80 proband chromosomes (frequency: 0.01) from Moroccan individuals or families with early onset and familial breast/ovarian cancer (Tazzite_2012_22425665). Results of two evolutionary models predicting the significance of specific sites in BRCA1 exon 11 were conflicting, 1 study finding the variant had a functional effect and the other finding it did not have a functional effect (Burk-Herrick_2005_16518693, Fleming_2003_12531920). The variant was also identified in dbSNP (ID: rs80356964) “With Uncertain significance,other allele”, ClinVar (classified uncertain significance by Counsyl, Ambry Genetics and BIC; and classification not provided by Invitae), Clinvitae (1x), LOVD 3.0 (1x), and BIC Database (1x, with unknown clinical importance, classification pending). The variant was not identified in UMD (unavailable), MutDB, GeneInsight-COGR, Cosmic, ARUP Laboratories, Zhejiang Colon Cancer Database, the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The p.Arg466 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact of the variant Gly to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

Breast Cancer Information Core (BIC) (BRCA1)

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

Mar 28, 2016

Counsyl

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.

not provided Uncertain:4

Aug 07, 2025

GeneDx

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); Also known as 1515C>G; Observed in individuals with a personal and/or family history of breast and/or ovarian cancer, in one patient co-occurring with a BRCA1 pathogenic variant (PMID: 22425665, 30199306, 32885271, 39541563, 40257527); This variant is associated with the following publications: (PMID: 16518693, 31131967, 12531920, 22425665, 30199306, 29884841, 32377563, 31911673, 32885271, 40257527, 15343273, 39541563)

Mar 07, 2017

Women's Health and Genetics/Laboratory Corporation of America, LabCorp

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Variant summary: The BRCA1 c.1396C>G (p.Arg466Gly) variant located in the serine-rich domain (via InterPro) involves the alteration of a non-conserved nucleotide, which 4/5 in silico tools predict a damaging outcome, although these predictions have yet to be functionally assessed. The variant of interest was absent in 121376 control chromosomes (ExAC). A publication cites the variant in an affected individual with limited information (ie, no cosegregation information). In addition, multiple clinical diagnostic laboratories classified this variant as uncertain significance. Therefore, until additional information becomes available (ie, clinical and functional studies), the variant of interest has been classified as a "Variant of Uncertain Significance (VUS)."

Jan 01, 2025

CeGaT Center for Human Genetics Tuebingen

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

BRCA1: PM2, PS4:Moderate, BP1, BP5

Jan 17, 2023

Quest Diagnostics Nichols Institute San Juan Capistrano

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

It has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In the published literature, the variant has been reported in individuals with breast and/or ovarian cancer (PMIDs: 30199306 (2018), 22425665 (2012)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is benign or damaging. Based on the available information, we are unable to determine the clinical significance of this variant.

Hereditary cancer-predisposing syndrome Uncertain:2 Benign:1

Jun 08, 2023

Color Diagnostics, LLC DBA Color Health

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This missense variant replaces arginine with glycine at codon 466 of the BRCA1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in two individuals affected with breast or ovarian cancer (PMID: 22425665, 30199306) and in a multifactorial analysis with likelihood ratios for pathogenicity based on co-occurrence with a pathogenic covariant and family history of 1.0673 and 0.9148, respectively (PMID: 31131967). This variant also has been reported in an individual affected with ovarian cancer that exhibited microsatellite instability and loss of MSH6 and the presence of a BRCA1 truncation variant in the last coding exon (PMID: 32885271). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

Mar 23, 2023

University of Washington Department of Laboratory Medicine, University of Washington

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: curation

Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673).

May 09, 2025

Ambry Genetics

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The p.R466G variant (also known as c.1396C>G), located in coding exon 9 of the BRCA1 gene, results from a C to G substitution at nucleotide position 1396. The arginine at codon 466 is replaced by glycine, an amino acid with dissimilar properties. This variant has been reported in breast cancer cohorts (Burk-Herrick A et al. Mamm Genome, 2006 Mar;17:257-70; Tazzite A et al. Gynecol Oncol, 2012 Jun;125:687-92; Abulkhair O et al. J Glob Oncol, 2018 Aug;4:1-9; Lerner-Ellis J et al. J Cancer Res Clin Oncol, 2021 Mar;147:871-879; Rawashdeh RR et al. JCO Glob Oncol, 2024 Nov;10:e2400352). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear.

Breast and/or ovarian cancer Uncertain:1

Jan 18, 2023

CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Hereditary breast ovarian cancer syndrome Uncertain:1

Dec 22, 2024

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 466 of the BRCA1 protein (p.Arg466Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with BRCA1-related conditions (PMID: 32885271). ClinVar contains an entry for this variant (Variation ID: 54240). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt BRCA1 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Benign	0.17
BayesDel_addAF	Pathogenic	0.16	D
BayesDel_noAF	Uncertain	0.0
CADD	Benign	19
DANN	Benign	0.96
DEOGEN2	Uncertain	0.52	D;.;.;.;T;T;.;.;T
Eigen	Benign	-0.55
Eigen_PC	Benign	-0.65
FATHMM_MKL	Benign	0.13	N
LIST_S2	Uncertain	0.88	D;D;D;D;D;D;D;D;D
M_CAP	Uncertain	0.24	D
MetaRNN	Uncertain	0.44	T;T;T;T;T;T;T;T;T
MetaSVM	Uncertain	0.030	D
MutationAssessor	Uncertain	2.4	M;M;.;.;.;.;.;.;.
PhyloP100		0.78
PrimateAI	Benign	0.17	T
PROVEAN	Pathogenic	-6.0	D;D;D;D;.;D;D;D;D
REVEL	Uncertain	0.48
Sift	Benign	0.035	D;D;D;D;.;D;D;D;D
Sift4G	Uncertain	0.019	D;D;D;D;.;D;.;D;D
Vest4		0.36
ClinPred		0.63	D
GERP RS		1.3
RBP_binding_hub_radar		0.0
RBP_regulation_power_radar		1.0
Varity_R		0.24
gMVP		0.15

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Other links and lift over

dbSNP: rs80356964; hg19: chr17-41246152;